Cancer deaths are higher among organ transplant recipients
the ONA take:
Transplant patients receive drugs to prevent rejection of the new organ; however, because those drugs suppress the patient’s immune system, they are more susceptible to cancers many years later.
In particular, transplant recipients in Australia have a high risk of skin cancer because of its high UV levels. Researchers at the University of Adelaide are working on understanding this risk and how cancers can be prevented in this population.
This research has uncovered a number of biomarkers that indicate if a transplant patient may be more likely to develop cancer.
The researchers note, however, that they as of yet have no real way of preventing those cancers from occurring. But in an effort to find a balance between ensuring transplanted organs are not rejected and reducing the risk of cancers in these patients, the research team is conducting further studies to determine what the impact reducing immunosuppressants will have on patients.
This research has uncovered a number of biomarkers that indicate if a transplant patient may be more likely to develop cancer
Sign Up for Free e-newsletters
- Distress, Neuroticism Predict Long-term Emotional Distress After Cancer Diagnosis
- Risk Factors for Arterial, Venous Thrombosis Differ in Polycythemia Vera
- Dietary Estrogens Reduced Efficacy of Novel Breast Cancer Therapy
- Patient Satisfaction Ratings Can Be Negatively Impacted by Nurse Staffing Ratio
- BRCA Mutation Improves Prognosis for 2-year Survival in Younger-onset TNBC
- Bacteria in Probiotics Carry Potential Risks for Immunocompromised Patients
- Pertuzumab Regimen Approved for Adjuvant, Neoadjuvant Therapy in Specific Breast Cancers
- Common Oncologic Emergencies That Occur With Multiple Myeloma
- Artificial Sweeteners and Cancer Risk (Fact Sheet)
- Blueberry Extract May Boost Efficacy of Radiotherapy for Cervical Cancer
- Resolving Vaginal Dryness in Women With a History of Breast Cancer
- Overall Survival Prolonged With HIPEC + Cytoreductive Surgery for Gastric Cancer
- Better Postoperative Outcomes With RAMIE for Esophageal Cancer
- Distinct Patterns of Shiny White Streaks Strong Indicator of Melanoma
- FDA Issues Warning for Rolapitant Injectable Emulsion in the Treatment of CINV
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|